Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free GENF Stock Alerts

Genflow Biosciences (GENF) Competitors

Genflow Biosciences logo
GBX 1.92 0.00 (0.00%)
As of 07/20/2026 10:48 AM Eastern
Compare

GENF vs. COIL, POLB, SAR, COS, and C4XD

Should you buy Genflow Biosciences stock or one of its competitors? MarketBeat compares Genflow Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genflow Biosciences include Roquefort Therapeutics (COIL), Poolbeg Pharma (POLB), Sareum (SAR), Collagen Solutions plc (COS.L) (COS), and C4X Discovery (C4XD). These companies are all part of the "biotechnology" industry.

How does Genflow Biosciences compare to Roquefort Therapeutics?

Genflow Biosciences (LON:GENF) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Genflow Biosciences is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

0.1% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 2.1% of Roquefort Therapeutics shares are owned by institutional investors. 25.8% of Genflow Biosciences shares are owned by insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Genflow Biosciences has a net margin of -170.64% compared to Roquefort Therapeutics' net margin of -57,057.07%. Genflow Biosciences' return on equity of 332.06% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Roquefort Therapeutics Neutral

Genflow Biosciences has a beta of 2.297, indicating that its stock price is 130% more volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market.

Summary

Roquefort Therapeutics beats Genflow Biosciences on 5 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

Poolbeg Pharma has a beta of 1.812, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.297, indicating that its stock price is 130% more volatile than the broader market.

1.5% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Poolbeg Pharma has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Genflow Biosciences -170.64%332.06%-58.66%

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.95 indicating that Genflow Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Poolbeg Pharma Negative
Genflow Biosciences Neutral

Summary

Genflow Biosciences beats Poolbeg Pharma on 7 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to Sareum?

Genflow Biosciences (LON:GENF) and Sareum (LON:SAR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

0.1% of Genflow Biosciences shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by company insiders. Comparatively, 35.7% of Sareum shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sareum has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Sareum's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
Sareum N/A -284.01%-113.80%

Genflow Biosciences has a beta of 2.297, indicating that its stock price is 130% more volatile than the broader market. Comparatively, Sareum has a beta of -1.08, indicating that its stock price is 208% less volatile than the broader market.

In the previous week, Sareum had 1 more articles in the media than Genflow Biosciences. MarketBeat recorded 1 mentions for Sareum and 0 mentions for Genflow Biosciences. Sareum's average media sentiment score of 0.34 beat Genflow Biosciences' score of 0.00 indicating that Sareum is being referred to more favorably in the news media.

Company Overall Sentiment
Genflow Biosciences Neutral
Sareum Neutral

Sareum is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
SareumN/AN/A-£5.28M-£3.90N/A

Summary

Genflow Biosciences beats Sareum on 7 of the 11 factors compared between the two stocks.

How does Genflow Biosciences compare to Collagen Solutions plc (COS.L)?

Genflow Biosciences (LON:GENF) and Collagen Solutions plc (COS.L) (LON:COS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

0.1% of Genflow Biosciences shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Collagen Solutions plc (COS.L) has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than Collagen Solutions plc (COS.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Collagen Solutions plc (COS.L)£4.01M0.00N/A-£0.80N/A

Collagen Solutions plc (COS.L) has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Collagen Solutions plc (COS.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
Collagen Solutions plc (COS.L) N/A N/A N/A

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled Collagen Solutions plc (COS.L)'saverage media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Collagen Solutions plc (COS.L) Neutral

Summary

Genflow Biosciences beats Collagen Solutions plc (COS.L) on 5 of the 8 factors compared between the two stocks.

How does Genflow Biosciences compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

In the previous week, C4X Discovery's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
C4X Discovery Neutral
Genflow Biosciences Neutral

C4X Discovery has a net margin of 42.81% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat C4X Discovery's return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Genflow Biosciences -170.64%332.06%-58.66%

C4X Discovery has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

C4X Discovery has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.297, indicating that its stock price is 130% more volatile than the broader market.

52.1% of C4X Discovery shares are owned by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are owned by institutional investors. 27.1% of C4X Discovery shares are owned by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

C4X Discovery beats Genflow Biosciences on 8 of the 10 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

GENF vs. The Competition

Export
MetricGenflow BiosciencesBiotechnology IndustryMedical SectorLON Exchange
Market Cap£10.90M£444.71M£6.81B£2.79B
Dividend YieldN/A3.90%2.67%6.16%
P/E Ratio-5.803.4926.97368.25
Price / SalesN/A6,249.84518.5784,392.87
Price / Cash3.0013.1349.7127.89
Price / Book7.7687.6810.677.59
Net Income-£1.76M-£96.07M£3.60B£5.89B
7 Day Performance-2.14%-0.59%-0.37%0.05%
1 Month Performance-7.85%1.23%1.80%-0.66%
1 Year Performance179.80%60.49%25.50%62.48%

Genflow Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GENF
Genflow Biosciences
N/AGBX 1.93
flat		N/A+188.6%£10.90MN/AN/A5
COIL
Roquefort Therapeutics
N/AGBX 10
flat		N/A-28.6%£42.68MN/AN/A9
POLB
Poolbeg Pharma
N/AGBX 6.05
-13.6%		N/A+100.0%£42.66MN/AN/A12
SAR
Sareum
N/AGBX 22
-4.3%		N/A+36.7%£31.87MN/AN/A3,211
COS
Collagen Solutions plc (COS.L)
N/AN/AN/AN/A£30.99M£4.01MN/A3,350

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:GENF) was last updated on 7/21/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel